



11. The compound of claim 1, wherein the compound has an effective permeability P_e for the blood brain barrier of at least about 8×10^{-6} cm/s.

12. The compound of claim 1, wherein the compound has a selectivity for nNOS versus iNOS of at least about 30.

13. The compound of claim 1, wherein the compound has a selectivity for nNOS versus eNOS of at least about 1000.

14. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

15. A method of treating or preventing a disease or disorder associated with nitric oxide synthase in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 1.

16. The method of claim 15, wherein the disease or disorder is a neurodegenerative disease or disorder.

17. The method of claim 15, wherein the disease or disorder is Alzheimer's disease.

18. The method of claim 15, wherein the disease or disorder is Huntington's disease.

19. The method of claim 15, wherein the disease or disorder is Parkinson's disease.

20. The method of claim 15, wherein the disease or disorder is amyotrophic lateral sclerosis (ALS).

21. The method of claim 15, wherein the disease or disorder is cerebral palsy.

22. The method of claim 15, wherein the disease or disorder is a migraine headache.

23. A method of inhibiting nitric oxide synthase (NOS) in a cell, the method comprising contacting the cell with the compound of claim 1.

* * * * *